

The Singapore Exchange Securities Trading Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and is not an offer to sell or the solicitation of an offer to acquire, purchase or subscribe for securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever.

GLENMARK PHARMACEUTICALS LIMITED
(the "Company")

**DISCLOSURE PURSUANT TO RULE 324(1) OF THE LISTING MANUAL OF
THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED**

Reference is made to the Company's U.S.\$200,000,000 4.5% cent. Senior Notes due 2021 (ISIN: XS1456577334; Common Code: 1456577334) (the "Notes") issued on 1 August 2016 and listed on the Singapore Exchange Securities Trading Limited (the "SGX-ST"). Reference is also made to the Company's announcement dated 9 December 2020 in relation to the redemption of U.S.\$182,500,000 in aggregate principal amount of its Notes, representing approximately 91.25% of the aggregate principal amount of the Notes at the time of initial listing.

The Company wishes to announce that the Company had on 11 December 2020 redeemed U.S.\$7,500,000 in aggregate principal amount of its Notes, representing approximately 3.75% of the aggregate principal amount of the Notes at the time of initial listing. As on the date of this announcement, U.S.\$10,000,000 in aggregate principal amount of Notes remain outstanding.

For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary & Compliance Officer